Newsbenzinga
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
· Published
Article summary
The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.
An excerpt from the original article.
Comments —
Loading comments…